Search
Roivant Sciences Ltd
ROIVAdd to Watchlist
38.880USD
+2.260+6.17%
Close 11-06 16:00（ET）
28.08BMarket Cap
LossP/E TTM
After-hours 17:02 (ET)38.930USD+0.080+0.21%
After-hours 17:02 (ET)Roivant Sciences Ltd (ROIV) Stock Price Target & Forecast
Analyst Rating
Based on 14 analysts giving stock ratings to Roivant Sciences Ltd in the past month.
Buy
7 Strong Buy
5 Buy
2 Hold
0 Sell
0 Strong Sell
Target Price
50.112USD+35.77%
ROIV Analyst Recommendation Trends
In the current month, ROIV has received 5 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. ROIV average Analyst price target in the last month is 50.112.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
7
7
6
6
6
6
6
5
5
5
6
6
6
6
6
6
2
2
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14
14
13
13
13
13
13
12
ROIV Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
8
16
12
1
0
37
Amgen Inc
AMGN
4
9
19
3
1
36
Eli Lilly and Co
LLY
10
19
3
1
0
33
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Alnylam Pharmaceuticals Inc
ALNY
7
17
8
0
0
32
AbbVie Inc
ABBV
8
18
6
0
0
32
Merck & Co Inc
MRK
7
16
8
0
0
31
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Gilead Sciences Inc
GILD
7
18
5
0
0
30
Bristol-Myers Squibb Co
BMY
5
6
18
1
0
30
Financial Forecasting
Based on analysts' estimates, ROIV EPS is projected to reach -0.380 in FY2027Q2, following reported EPS of -0.263 in FY2027Q1. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q3
FY2026Q4
FY2027Q1
FY2027Q2
FY2027Q3
Forecast
-0.32
-0.35
-0.33
-0.38
-0.38
Actual
-0.38
0.42
-0.26
--
--
Surprise
-20.11%
+222.28%
+20.04%
--
--
FAQs
What is Roivant Sciences Ltd's expected revenue for the next quarter?
Roivant Sciences Ltd's expected revenue is 4.11M.
What is Roivant Sciences Ltd's price target?
Analysts forecast that Roivant Sciences Ltd's price target is USD 50.11, with the highest forecast at USD 62.00 and the lowest forecast at USD 41.00.
How have Roivant Sciences LtdROIV's recent earnings per share performed?
The market expectation was USD -0.26, while Roivant Sciences LtdROIV's earnings per share (EPS) for the previous quarter was USD 0.42. EPS for the next quarter is expected at USD -0.38.
What is the analyst rating for Roivant Sciences Ltd?
Based on the ratings of Roivant Sciences Ltd's stock from 14 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.